GHENT, BELGIUM--(Marketwire - Feb 18, 2013) - Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, announces its exclusive agreement with Biotech Medical Aesthetic SAS for distributing its River 8 veneers worldwide.
River 8 -- the revolutionary, painless, and affordable porcelain veneer solution for discolored, damaged, stained or misaligned teeth -- will be produced by Remedent and globally distributed by Biotech International who are already active in over 40 countries as market leader in dental and orthopedic surgery implants.
Both partners have agreed upon a renewable 5 years contract with a first order of 1 million euros (1,35 million USD).
"We are very excited about this partnership," comments Mr. Guy De Vreese, CEO of Remedent. "The River 8 concept and technology is going to radically transform cosmetic dentistry worldwide, achieving a whitening result that lasts without bleaching."
Mr. Philippe Veran, CEO of Biotech, adds: "This cooperation fits perfectly in our vision: we believe cosmetic solutions in general and veneers in particular will have their undisputed place in every dental practice of tomorrow."
Remedent Inc. creates state-of-the-art dental technologies and marketing concepts. Famous brands are GlamSmile, Remecure, White Boost, Formulation +, and River 8. Headquartered in Belgium, Remedent Inc. manufactures, markets and distributes its products and concepts to more than 25 countries worldwide. Remedent Inc. is publicly listed and focuses on B2B, delivering products to the dental professional, as well as B2C approaches, helping consumers to obtain their dream smile through its Smile Consultancy Concept.
Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," "projects," "project," to be uncertain and forward-looking. Actual results could differ materially because of factors such as Remedent's ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent's business, please refer to the risk factors described in Remedent's filings with the Securities and Exchange Commission, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q.